MikeTrendsTrends right now
AI: reposAPI

search

GIPR

Trends

  1. 1
    Insilico Medicine picks AI-designed obesity drug candidate ISM1354●Insilico Medicine nominates AI-designed ISM1354 GIPR antagonist for obesity✉newsHealthMedicine1 h ago

    Hong Kong-based biotech Insilico Medicine has nominated ISM1354, a GIPR antagonist designed with its generative AI platform, as a preclinical development candidate for obesity and related metabolic disorders. It is the latest example of artificial intelligence compressing early drug discovery, and observers see it as a test of whether AI-designed molecules can advance into serious clinical pipelines for weight-loss treatment.